Generics North America (NAFTA) Industry Guide 2017-2021

Generics North America (NAFTA) Industry Guide 2017-2021


  • Products Id :- MLIG1744-03
  • |
  • Pages: 66
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Generics North America (NAFTA) Industry Guide 2017-2021

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of USD1,11,669.7 million in 2016.The Mexico was the fastest growing country, with a CAGR of 14.3% over the 2012-16 period.

Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of USD1,01,790.0 million in 2016. This was followed by Mexico and Canada, with a value of USD5,430.1 and USD4,449.6 million, respectively.

The US is expected to lead the generics industry in the NAFTA bloc, with a value of USD1,48,130.6 million in 2021, followed by Mexico and Canada with expected values of USD10,769.6 and USD6,409.3 million, respectively.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market

Leading company profiles reveal details of key generics market players' NAFTA operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume

Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to buy

What was the size of the NAFTA generics market by value in 2016?

What will be the size of the NAFTA generics market in 2021?

What factors are affecting the strength of competition in the NAFTA generics market?

How has the market performed over the last five years?

How large is the NAFTA generics market in relation to its regional counterparts?



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Introduction

What is this report about?

Who is the target reader?

How to use this report

Definitions

NAFTA Generics

Industry Outlook

Generics in Canada

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Mexico

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The United States 40

Market Overview 40

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Company Profiles

Leading Companies

Appendix

Methodology

About MarketLine

List of Figures

Figure 1: NAFTA countries generics industry, revenue (USDm), 2012-21

Figure 2: NAFTA countries generics industry, revenue (USDm), 2012-16

Figure 3: NAFTA countries generics industry forecast, revenue (USDm), 2016-21

Figure 4: Canada generics market value: USD million, 2012-16

Figure 5: Canada generics market volume: % of total pharma volume, 2012-16

Figure 6: Canada generics market geography segmentation: % share, by value, 2016

Figure 7: Canada generics market value forecast: USD million, 2016-21

Figure 8: Canada generics market volume forecast: % of total pharma volume, 2016-21

Figure 9: Forces driving competition in the generics market in Canada, 2016

Figure 10: Drivers of buyer power in the generics market in Canada, 2016

Figure 11: Drivers of supplier power in the generics market in Canada, 2016

Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016

Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2016

Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2016

Figure 15: Mexico generics market value: USD million, 2012-16

Figure 16: Mexico generics market volume: % of total pharma volume, 2012-16

Figure 17: Mexico generics market geography segmentation: % share, by value, 2016

Figure 18: Mexico generics market value forecast: USD million, 2016-21

Figure 19: Mexico generics market volume forecast: % of total pharma volume, 2016-21

Figure 20: Forces driving competition in the generics market in Mexico, 2016

Figure 21: Drivers of buyer power in the generics market in Mexico, 2016

Figure 22: Drivers of supplier power in the generics market in Mexico, 2016

Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016

Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2016

Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2016

Figure 26: United States generics market value: USD billion, 2012-16

Figure 27: United States generics market volume: % of total pharma volume, 2012-16

Figure 28: United States generics market geography segmentation: % share, by value, 2016

Figure 29: United States generics market value forecast: USD billion, 2016-21

Figure 30: United States generics market volume forecast: % of total pharma volume, 2016-21

Figure 31: Forces driving competition in the generics market in the United States, 2016

Figure 32: Drivers of buyer power in the generics market in the United States, 2016

Figure 33: Drivers of supplier power in the generics market in the United States, 2016

Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016

Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2016

Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2016

Figure 37: Mylan N.V.: revenues & profitability

Figure 38: Mylan N.V.: assets & liabilities

Figure 39: Novartis AG: revenues & profitability

Figure 40: Novartis AG: assets & liabilities

Figure 41: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 42: Teva Pharmaceutical Industries Limited: assets & liabilities

List of Tables

Table 1: NAFTA countries generics industry, revenue (USDm), 2012-21

Table 2: NAFTA countries generics industry, revenue (USDm), 2012-16

Table 3: NAFTA countries generics industry forecast, revenue (USDm), 2016-21

Table 4: Canada generics market value: USD million, 2012-16

Table 5: Canada generics market volume: % of total pharma volume, 2012-16

Table 6: Canada generics market geography segmentation: USD million, 2016

Table 7: Canada generics market value forecast: USD million, 2016-21

Table 8: Canada generics market volume forecast: % of total pharma volume, 2016-21

Table 31: Canada size of population (million), 2012-16

Table 32: Canada gdp (constant 2005 prices, USD billion), 2012-16

Table 33: Canada gdp (current prices, USD billion), 2012-16

Table 34: Canada inflation, 2012-16

Table 35: Canada consumer price index (absolute), 2012-16

Table 36: Canada exchange rate, 2012-16

Table 9: Mexico generics market value: USD million, 2012-16

Table 10: Mexico generics market volume: % of total pharma volume, 2012-16

Table 11: Mexico generics market geography segmentation: USD million, 2016

Table 12: Mexico generics market value forecast: USD million, 2016-21

Table 13: Mexico generics market volume forecast: % of total pharma volume, 2016-21

Table 14: Mexico size of population (million), 2012-16

Table 15: Mexico gdp (constant 2005 prices, USD billion), 2012-16

Table 16: Mexico gdp (current prices, USD billion), 2012-16

Table 17: Mexico inflation, 2012-16

Table 18: Mexico consumer price index (absolute), 2012-16

Table 19: Mexico exchange rate, 2012-16

Table 20: United States generics market value: USD billion, 2012-16

Table 21: United States generics market volume: % of total pharma volume, 2012-16

Table 22: United States generics market geography segmentation: USD billion, 2016

Table 23: United States generics market value forecast: USD billion, 2016-21

Table 24: United States generics market volume forecast: % of total pharma volume, 2016-21

Table 25: United States size of population (million), 2012-16

Table 26: United States gdp (constant 2005 prices, USD billion), 2012-16

Table 27: United States gdp (current prices, USD billion), 2012-16

Table 28: United States inflation, 2012-16

Table 29: United States consumer price index (absolute), 2012-16

Table 30: United States exchange rate, 2012-15

Table 37: Apotex, Inc.: key facts

Table 38: Mylan N.V.: key facts

Table 39: Mylan N.V.: key financials (USD)

Table 40: Mylan N.V.: key financial ratios

Table 41: Novartis AG: key facts

Table 42: Novartis AG: key financials (USD)

Table 43: Novartis AG: key financial ratios

Table 44: Teva Pharmaceutical Industries Limited: key facts

Table 45: Teva Pharmaceutical Industries Limited: key financials (USD)

Table 46: Teva Pharmaceutical Industries Limited: key financial ratios

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license
Single User License
USD 795 INR 55650
Site License
USD 1590 INR 111300
Corporate User License
USD 2385 INR 166950

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com